Serum-free GMP culture conditions have been developed for the expansion, differentiation, purging and gene transfer of hemapoietic stem cells. Under these conditions, efficient purging (Ͼ3 logs) with recombinant immunotoxins or denditric cell differentiation can readily be obteined. While extended static culture (Ͼ7 d) leads to telomer shortening and decreased telomerase activity, shorter culture periods maintain telomer length and increase telomerase activity. Human peripheral blood derived hematopoietic stem cells (HPSC) retain all biological in vitro and in vivo properties for long term hematopoeitic reconstituion. The same GMP medium (CellGro=AE) also allows serum free production of retroviral vector containing medium using the GALV pseudotyped packaging cell line PG13/LN. In a phase I/II trial of HPSC autotransplantation for patients with CML, serum-free ex vivo gene marking is performed after in vivo and in vitro purging of Ph+-cells.The marker is present in the peripheral blood for Ͼ200 days. Prelimijnary analyses suggest that up to 10% of those cells from the ex vivo culture that contribute to long-term hematopoiesis contain the transgene. A new method of viral integration site analysis demonstrates oligoclonal hematopoiesis with different clones of the marked population detectable at varying time points. Follicular lymphoma (FL) is characterized by indolent clinical course and high-response rates to conventional therapy. Still, a significant number of patients relapse and some of them present with transformation to an agressive, poorly treatment-responsive, large-cell lymphoma. The benefit of high-dose therapy with hematopoietic stem cell support for patients with low-grade NHL is still controversial.
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S5c
We treated 111 patients with advanced stage low-grade FL with high-dose therapy and peripheral blood stem cell (PBSC) support. Seventy patients were enrolled in first remission, whereas 41 were treated in second or higher S10 remission. All patients were enrolled at best response following induction therapy, consisting of a median of 5 cycles of anthracycline-containing regimens. Seventeen patients received radiotherapy as part of their induction. High-dose therapy consisted of total-body irradiation plus cyclophosphamide and of BEAM in 8 patients. Autografts contained 8.1 Ϯ 0.6 CD34+ cells/kg BW (Mean Ϯ SEM). CD34 selected cells were transplanted in 15 patients.
At a median follow up of 44.2 months from PBSCT, 93 patients are alive, with a probability of overall and relapsefree survival of 83% and 64% respectively. Five toxic death occured at a median time of 13.2 monthsfollowing PBSCT. Nine patients died due to the progression of the disease. Male gender, involvement of more than 8 lymphnode areas, extra-nodal involvement and previous radiotherapy were negative prognostic factors for relapse (RFS: 45% vs 79%, p = 0.048; 78% vs 40%, p = 0.02, and 67% vs 22%, p = 0.001 respectively). Bulky-disease was present in 30 patients and did not have an influence on disease recurrence or survival. No differences overall and relapse-free survival were noted between patients in stage ՅIII and IV. The importance of an efficient induction therapy was indicated by a significantly better RFS in patients who had achieved complete remission at the time PBSC mobilization (83% vs 57%, p = 0.036). Confirming our previous data on a smaller series of patients, a significant difference in the probabilities of RFS was noted between patients transplanted in first remission and those included in second or higher remission(78% vs 43%, p = 0.043). Our study suggests that high-dose therapy with PBSC-support, when performed early in the course of the disease, before the development of resistance to chemo-and radiotherapy, may improve overall and relapse-free survival in patients with advancedstage low-grade FL. For patients at high-risk for relapse, adjuvant treatments based on principles other than cytotxic are envisaged. We are studying the use of ex vivo activated T-cells loaded up with a CD3 × CD19 bi-specific antibody or of B-cell-specific antibodies conjugated to 213 bismuth, an alpha-emitting radio-isotope. Background: The outcome of autologous stem cell transplantation has been shown to depend on different risk factors including remission status before transplant and contamination of tumor cells of the graft. In the present analysis, the impact of previous induction and consolidation therapy was assessed as a possible determinant for the outcome after autologous stem cell transplantation. , days 1-4). In this protocol, a total of 137 patients were treated and subsequently patients with an HLA-identical sibling were offered allo-BMT (n = 14). Those without a donor were allocated at the time of CR to either autologous bone marrow or peripheral blood stem cell transplantation (n = 12) or to a further consolidation course (n = 67).
S5d: Induction and Consolidation Therapy

Patients and methods:
Finally, nine patients received IDA (12 mg/m 2 , days 1-3)/Ara-C (2-3 g/m 2 /d, days 1+3+5+7 and, reduced, 1+3+5, protocol AML '96).
Autologous transplantation was performed either with stem cells from bone marrow (until 1993) or peripheral blood (after 1993) . Results: From the 358 patients who entered the trials since 1985, 226 reached CR. CR varied significantly within the three groups, showing higher CR (89%) in the '96 followed by the '91 + '93 (68%) and '85 + '89 (56%) (p = 0.008) trials. 
S11
From the patients allocated to autologous transplantation, only 17 were grafted in the first group, 11 in the second and 9 in the third ( Table 2 ). The remaining patients relapsed before transplantation (n = 14) or had an insufficient stem cell graft (n = 2). Of the 37 patients undergoing autologous transplantation, 4 died from transplant-related toxicity (AML '85 + '89:3; AML '96: 1). LFS increased constantly within the three groups from 35% to 45% and 78% respectively. The differences were mainly due to the decrease in RI. Results were confirmed performing an intention-to-treat analysis. 
Conclusions:
Present results confirm the importance of induction and remission therapy for LFS following autologous transplantation. This result is even more pronounced, in vue of the increased median age and the shorter diagnosis transplant interval of the '96 and '91 + '93 groups as compared to the '85 + '89 grroup. Improved LFS was a consequence of reduced RI and most probably due to the more effective induction and consolidation therapy.
